Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common subtype of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….
Targeted Vertebral Fracture Assessment
A Canadian study sought to identify individuals at high fracture risk and provide them with pharmacotherapy to prevent fractures. They found the assessment of hip and lumbar dual-energy X-ray absorptiometry scans for vertebral fracture can be useful in the identification of women and men aged 70 years and older who should qualify for anti-osteoporosis treatment…
BMD Not a Reliable Predictor of Vertebral Fragility Fracture in Older Women
NEW YORK (Reuters Health)—Bone mineral density (BMD), particularly lumbar BMD, may not reliably indicate the presence of asymptomatic vertebral fragility fractures in post-menopausal women, new findings suggest. In a study online May 9 in Bone, Italian researchers found such fractures were common among women seen at an osteoporosis clinic, yet the vast majority had not…
Undetected Fractures Linked to Back Pain in Older Men
(Reuters Health)—About three in five older men with tiny spinal fractures related to osteoporosis reported new or worsening back pain in a new study. Only about one-quarter of new vertebral fractures are diagnosed by a doctor, the study team writes in their September 7 online report in Journal of Bone and Mineral Research, though the…
Denosumab Linked to Rebound-Associated Fractures in Nine Patients
NEW YORK (Reuters Health)—Patients can develop rebound-associated vertebral fractures after stopping denosumab, a new report of nine cases shows. All of the patients were considered to be at low risk of fracture, and the fractures occurred within nine to 16 months of their last injection, Dr. Olivier Lamy and colleagues from Lausanne University Hospital in Switzerland…
Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
(Reuters)—Amgen Inc. and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study. The topline results, from a Fracture study in postmenopausal women with osteoporosis (FRAME), showed that the drug romosozumab met a…
Concrete Relief for Vertebral Fractures
PVA reduces fracture pain—but is it overused?
Reading RHEUM
Handpicked Reviews of Contemporary Literature